These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23334071)

  • 41. Use of atypical antipsychotics in refractory depression and anxiety.
    Nemeroff CB
    J Clin Psychiatry; 2005; 66 Suppl 8():13-21. PubMed ID: 16336032
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effect of scopolamine on depression in mice].
    Ji CX; Zhang JJ
    Yao Xue Xue Bao; 2011 Apr; 46(4):400-5. PubMed ID: 21751493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression.
    Romeo B; Choucha W; Fossati P; Rotge JY
    Psychiatry Res; 2015 Dec; 230(2):682-8. PubMed ID: 26548981
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of antidepressants in the treatment of adolescents and young adults with depression and substance use disorders: a systematic review and meta-analysis.
    Zhou X; Qin B; Del Giovane C; Pan J; Gentile S; Liu Y; Lan X; Yu J; Xie P
    Addiction; 2015 Jan; 110(1):38-48. PubMed ID: 25098732
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy.
    Widman AJ; McMahon LL
    Proc Natl Acad Sci U S A; 2018 Mar; 115(13):E3007-E3016. PubMed ID: 29531088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials.
    Faridhosseini F; Sadeghi R; Farid L; Pourgholami M
    Hum Psychopharmacol; 2014 May; 29(3):216-23. PubMed ID: 24911574
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action.
    Lopresti AL; Drummond PD
    Hum Psychopharmacol; 2014 Nov; 29(6):517-27. PubMed ID: 25384672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis.
    Apfel CC; Zhang K; George E; Shi S; Jalota L; Hornuss C; Fero KE; Heidrich F; Pergolizzi JV; Cakmakkaya OS; Kranke P
    Clin Ther; 2010 Nov; 32(12):1987-2002. PubMed ID: 21118734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. No antidepressant effect of biperiden compared with placebo in depression: a double-blind 6-week clinical trial.
    Gillin JC; Lauriello J; Kelsoe JR; Rapaport M; Golshan S; Kenny WM; Sutton L
    Psychiatry Res; 1995 Sep; 58(2):99-105. PubMed ID: 8570773
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of Antidepressants for Depression in Alzheimer's Disease: Systematic Review and Meta-Analysis.
    Orgeta V; Tabet N; Nilforooshan R; Howard R
    J Alzheimers Dis; 2017; 58(3):725-733. PubMed ID: 28505970
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of depression--newer pharmacotherapies.
    Mulrow CD; Williams JW; Trivedi M; Chiquette E; Aguilar C; Cornell JE; Badgett R; Noël PH; Lawrence V; Lee S; Luther M; Ramirez G; Richardson WS; Stamm K
    Psychopharmacol Bull; 1998; 34(4):409-795. PubMed ID: 10513454
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of antidepressant responses in patients with bipolar vs. unipolar depression: a meta-analytic review.
    Vázquez G; Tondo L; Baldessarini RJ
    Pharmacopsychiatry; 2011 Jan; 44(1):21-6. PubMed ID: 21031345
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antidepressant treatments in the 21st century.
    Nestler EJ
    Biol Psychiatry; 1998 Oct; 44(7):526-33. PubMed ID: 9787876
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design, Synthesis, and Activity Evaluation of Fluorine-Containing Scopolamine Analogues as Potential Antidepressants.
    Wang L; Zhu X; Wang B; Wang Y; Wang M; Yang S; Su C; Chang J; Zhu B
    J Med Chem; 2024 Apr; 67(7):5391-5420. PubMed ID: 38354305
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response to commentary by Rhew and colleagues on: Depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence.
    Kunutsor SK; Seidu S; Khunti K
    Ann Med; 2019 Feb; 51(1):99-100. PubMed ID: 30931634
    [No Abstract]   [Full Text] [Related]  

  • 57. Commentary on: Depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence.
    Rhew K; Reams VZ; Brown JD; Winterstein AG
    Ann Med; 2019 Feb; 51(1):97-98. PubMed ID: 30801227
    [No Abstract]   [Full Text] [Related]  

  • 58. Relative antidepressant activity of various chemical groups.
    SAINZ A; BIGELOW N
    Psychiatr Q; 1962 Oct; 36():633-54. PubMed ID: 13986479
    [No Abstract]   [Full Text] [Related]  

  • 59. Scopolamine and depression: a role for muscarinic antagonism?
    Hasselmann H
    CNS Neurol Disord Drug Targets; 2014; 13(4):673-83. PubMed ID: 24938776
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Interest of scopolamine as a treatment of major depressive disorder].
    Rigal A; Mouchabac S; Peretti CS
    Encephale; 2016 Dec; 42(6):568-573. PubMed ID: 27623122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.